Project Grant R43HL164247
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $529,283 to JB Healthtech, Inc. on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop and advance a dual-mode wearable continuous non-invasive blood pressure monitor for enhanced diagnosis and clinical management of preeclampsia in pregnancy. The recipient is developing NeoBP, a highly accurate continuous non-invasive blood pressure device that operates...
- The National Institute of Biomedical Imaging and Bioengineering awarded Rutgers, The State University $235,500 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop BPALERT, a non-invasive, AI-enhanced continuous blood pressure monitoring system for neonates in neonatal intensive care units. The project combines AI-driven blood pressure estimation from photoplethysmography signals with periodic...
- Dynocardia Inc. received a $256,000 National Science Foundation Project Grant to advance development of a novel continuous, cuffless blood pressure monitoring device. Funded through the NSF Engineering Directorate's SBIR program, the award will support Dynocardia's efforts to address motion artifacts and enable accurate, beat-to-beat blood pressure measurements in hospital intensive care and operating room settings. Accurate 24-hour blood pressure monitoring has potential to significantly...
- Ovid BP Systems Inc. received a $713,199 Project Grant award from the National Institutes of Health's National Heart, Lung and Blood Institute on April 15, 2021 to develop a blood pressure monitoring system using video recording on smart cameras. The goal of the Cardiovascular Diseases Research program, CFDA #93.837, is to support heart and vascular research. Under this award, Ovid BP will assess the feasibility of using video-based algorithms to accurately measure blood pressure through...
- The National Heart, Lung, and Blood Institute awarded Autonomous Healthcare Inc. $305,999 on September 1, 2026, under the Small Business Innovation Research (SBIR) program to conduct a Phase I feasibility study of E-Fusion, a bedside clinical decision support system designed to assist anesthesiologists, anesthetists, and critical care nurses with vasopressor titration and blood pressure management during surgery and in the intensive care unit. The system monitors mean arterial pressure (MAP) and...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $1,491,464 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, for Project Grant R01HL178770, a research study comparing ambulatory blood pressure monitoring (ABPM) to wrist-worn home blood pressure monitoring (HBPM) in assessing end-organ damage. The study, titled AW-COMPARE, will evaluate whether wrist-worn HBPM devices can replace ABPM as the reference standard for...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Institute of Biomedical Imaging and Bioengineering awarded George Mason University $265,018 on August 15, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a disposable wearable ultrasound patch for real-time, noninvasive monitoring of cardiac output and blood pressure in neonates and infants following cardiac surgery. The project addresses the absence of continuous hemodynamic monitoring solutions...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $706,159 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a smart wearable continuous cuffless blood pressure, cardiac, and respiratory monitoring system agnostic to skin tone. The recipient will design and build an innovative wearable device integrating multiple non-invasive physiological sensors on the wrist to provide health-grade continuous...
DEVELOPMENT OF A HIGHLY ACCURATE WRIST/ANKLE-MOUNT NON-INVASIVE BLOOD PRESSURE MONITOR FOR NEONATAL PATIENTS - SUMMARY/ABSTRACT MORE THAN 340,000 NEONATES ARE ADMITTED TO THE NEONATAL INTENSIVE CARE UNIT (NICU) EACH YEAR IN THE UNITED STATES. MONITORING ARTERIAL BLOOD PRESSURE (BP) FOR THEM, PARTICULARLY PRETERM LOW-BIRTHWEIGHT NEWBORNS, CAN BE CHALLENGING. THE OSCILLOMETRIC (OSC) BRACHIAL CUFF IS MUCH LESS ACCURATE IN NEONATES THAN ADULTS BECAUSE IT DERIVES SYSTOLIC AND DIASTOLIC PRESSURES USING POPULATION-BASED RATIOS. WITH LOWER BP, NEONATES AS A GROUP ARE STATISTICALLY UNDERREPRESENTED IN THESE RATIOS, THUS THEIR BP MEASUREMENTS TEND TO BE ERRONEOUS. THE STANDARD METHOD FOR NEONATAL BP MONITORING IS VIA THE UMBILICAL ARTERIAL CATHETER (UAC). HOWEVER, UAC FAILS TO WORK FOR APPROXIMATELY 10% OF PATIENTS WHEN BOTH UMBILICAL ARTERIES ARE DAMAGED OR REGRESS AFTER BIRTH. FOR THESE PATIENTS, THERE IS NO ALTERNATIVE AVAILABLE. UAC ALSO CARRIES SIGNIFICANT RISKS INCLUDING THROMBOSIS, HEMATOMAS, INFECTIONS, AND EVEN DEATH. TO ADDRESS THIS UNMET CLINICAL NEED OF NEONATAL BP MONITORING, JB HEALTHTECH, INC. (JBH) IS DEVELOPING A HIGHLY ACCURATE NON-INVASIVE BP MONITOR NEOBPTM THAT OPERATES IN 3 MODES. ITS CONTINUOUS MODE PROVIDES HIGH-FIDELITY ARTERIAL BP WAVEFORMS SIMILAR TO UAC, TO DERIVE ARTERIAL PRESSURES, RESPIRATION RATE, AND A SUITE OF HEMODYNAMIC PARAMETERS. ITS INTERMITTENT MODE GIVES A CONVENIENT BP SNAPSHOT AND HEART RATE, SIMILAR TO OSC. ITS PERIODIC MODE RUNS AT PREDEFINED RUNNING/RESTING TIME INTERVALS FOR ANY CLINICAL NEEDS IN BETWEEN. NEOBP IS BASED ON A VOLUME CLAMP (VC) TECHNOLOGY, WHICH IS ADVANTAGEOUS OVER OTHER TECHNOLOGIES, SUCH AS STATISTICAL MODELING WHERE NEONATES ARE UNDERREPRESENTED, LESS ACCURATE DEVICES WITH AIRBAGS ONLY, AND CUFFLESS DEVICES DEPENDING ON CALIBRATION WITH UAC OR OSC FOR EVERY USE. USING A NOVEL CLOSED-FORM THEORETICAL FRAMEWORK WITHOUT EMPIRICAL ELEMENTS, WE DYNAMICALLY BUILD THE PATIENT-SPECIFIC PRESSURE-VOLUME FUNCTION AND SOLVED A LONG-STANDING INACCURACY PROBLEM OF THE BP INDUSTRY. WE HAVE IMPLEMENTED THE INNOVATIVE ALGORITHMS ON THE PROTOTYPE, INITIATED PRELIMINARY ADULT CLINICAL TESTING, AND FILED THREE US PATENT APPLICATIONS. JBH HAS STRONG ENGINEERING EXPERTISE IN MEDICAL DEVICE DEVELOPMENT. WE ALSO HAVE PARTNERED WITH NEONATOLOGISTS AND CARDIOLOGISTS TO BENEFIT FROM THEIR CLINICAL EXPERIENCES AND INSIGHTS. WITH THIS DIVERSE, COMPLEMENTARY TEAM, WE WILL ADVANCE OUR DEVICE FROM PROTOTYPE TO PRACTICE. THE TASKS TO TAKE NEOBP INTO THE NICU INCLUDE HARDWARE REDESIGNS AND RIGOROUS CLINICAL TESTS. IN THIS PHASE I SBIR PROJECT, WE WILL BUILD OUR SECOND-GENERATION HARDWARE AND NEONATAL CUFFS MEETING PRODUCT SPECIFICATION MATRIXES TO RUN CLINICAL TESTS. WE WILL ALSO VALIDATE THE ACCURACY OF NEOBP AGAINST THE STANDARD OF CARE UAC TO DEMONSTRATE ITS FEASIBILITY. A SUCCESSFUL COMPARATIVE STUDY IN THE NICU WILL BE THE MILESTONE FOR THE PROJECT TO ADVANCE TO PHASE II. NEOBP WOULD BE THE FIRST HIGHLY ACCURATE NON- INVASIVE BP MONITOR IN THE NICU, PROVIDE A SIMPLE AND RELIABLE WAY TO MEASURE BP FOR ALL NEONATES. WITH ACCURACY COMPARABLE TO UAC, NEOBP WILL ELIMINATE UAC-RELATED COMPLICATIONS AND BECOME AN INDISPENSABLE TOOL IN EVERY NEONATOLOGIST'S ARMAMENTARIUM. IN PHASE II WE WILL FURTHER TEST IT IN MULTI-CENTER CLINICAL STUDIES, RESOLVE ANY CLINICAL RELATED ISSUES, REDESIGN IT FOR MANUFACTURABILITY, AND RECEIVE FDA 510(K) CLEARANCE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 6/25/25 | ||
| Not listed | $0 | 6/6/24 | ||
| Not listed | $55.0k | 4/26/23 | ||
| Not listed | $55.0k | 4/26/23 | ||
| Not listed | $300.0k | 5/24/22 |